← Back to Clinical Trials
Recruiting NCT06685367

The Cost-effectiveness of Artificial Intelligence Acute Kidney Injury Prediction Auxiliary Software (Acura AKI)

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Acute Kidney Injury
Sponsor Huede Healthtech Co., Ltd.
Study Type INTERVENTIONAL
Phase N/A
Enrollment 3,600
Sex ALL
Min Age 20 Years
Max Age N/A
Start Date 2024-10-17
Completion 2025-09-15
Interventions
Acura AKI

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

"Huede" AI Aided AKI Prediction Software, Acura AKI, uses machine learning algorithms to predict the risk of AKI within the next 24 hours and provide a ranking of feature importance. By using Acura AKI, physicians can assess the risk of AKI, focusing on high-risk patients to provide care decisions. This study will be conducted in a prospective randomized clinical trial in adult ICUs, implementing the Acura AKI system for predicting AKI. The study aims to determine whether early prediction and intervention using the Acura AKI system can improve the outcomes of critically ill patients with adverse kidney conditions. The study endpoint is to evaluate the cost-effectiveness of using Acura AKI, including the incidence of AKI, dialysis rates, mortality rates, length of hospital stay, and treatment costs.

Eligibility Criteria

Inclusion Criteria: * Over 20 years old * Admitted to adult ICU * Hospital stay of more than 30 hours Exclusion Criteria: * Known to have acute kidney injury at enrollment * Currently undergoing hemodialysis treatment * No available blood or urine test data * Pregnant women * HIV-positive patients * Those who have not provided informed consent form * Regarded as unsuitable for inclusion in the trial by the researcher

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}